- Home
- BIIB vs YPF Comparison
BIIB vs YPF Comparison
Compare BIIB & YPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- YPF
- Stock Information
- Founded
- BIIB 1978
- YPF 1977
- Country
- BIIB United States
- YPF Argentina
- Employees
- BIIB N/A
- YPF N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- YPF Integrated oil Companies
- Sector
- BIIB Health Care
- YPF Energy
- Exchange
- BIIB Nasdaq
- YPF Nasdaq
- Market Cap
- BIIB 19.9B
- YPF 16.8B
- IPO Year
- BIIB 1991
- YPF 1993
- Fundamental
- Price
- BIIB $118.84
- YPF $31.98
- Analyst Decision
- BIIB Buy
- YPF Buy
- Analyst Count
- BIIB 28
- YPF 7
- Target Price
- BIIB $218.29
- YPF $40.73
- AVG Volume (30 Days)
- BIIB 1.8M
- YPF 2.5M
- Earning Date
- BIIB 05-01-2025
- YPF 03-07-2025
- Dividend Yield
- BIIB N/A
- YPF N/A
- EPS Growth
- BIIB 40.28
- YPF N/A
- EPS
- BIIB 11.18
- YPF 5.14
- Revenue
- BIIB $9,675,900,000.00
- YPF $17,356,963,208.00
- Revenue This Year
- BIIB N/A
- YPF $2.74
- Revenue Next Year
- BIIB N/A
- YPF N/A
- P/E Ratio
- BIIB $10.63
- YPF $6.41
- Revenue Growth
- BIIB N/A
- YPF 226.28
- 52 Week Low
- BIIB $110.04
- YPF $16.18
- 52 Week High
- BIIB $238.00
- YPF $47.43
- Technical
- Relative Strength Index (RSI)
- BIIB 40.59
- YPF 47.05
- Support Level
- BIIB $117.21
- YPF $31.34
- Resistance Level
- BIIB $121.75
- YPF $34.02
- Average True Range (ATR)
- BIIB 4.87
- YPF 2.27
- MACD
- BIIB 0.66
- YPF 0.28
- Stochastic Oscillator
- BIIB 64.09
- YPF 70.79
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About YPF YPF Sociedad Anonima
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.